Синдром гиперпролактинемии и аденомы гипофиза: тактика ведения пациентов
Иловайская И.А., Уханова Ю.А. Синдром гиперпролактинемии и аденомы гипофиза: тактика ведения пациентов. FOCUS Эндокринология. 2021; 4: 15–18. DOI: 10.47407/ef2021.2.4.0044
Ilovaуskaya I.A., Ukhanova Yu.A. Hyperprolactinemia and pituitary adenoma: management of patients. FOCUS Endocrinology. 2021; 4: 15–18. DOI: 10.47407/ef2021.2.4.0044
Гиперпролактинемия – это распространенное эндокринное расстройство, являющееся важной проблемой, особенно среди пациентов репродуктивного возраста. Грамотный алгоритм диагностики необходим для постановки правильного диагноза и назначения подходящего лечения. Поэтому данная патология требует преемственности врачей смежных специальностей, в первую очередь эндокринологов, гинекологов, лучевых диагностов и нейрохирургов. В настоящее время применение современных лекарственных препаратов, преимущественно селективных агонистов дофаминовых рецепторов, позволяет достичь нормализации уровня пролактина, восстановления репродуктивной функции, а также улучшить в целом качество жизни среди пациентов с патологической гиперпролактинемией.
Ключевые слова: гиперпролактинемия, аденома гипофиза, пролактинома.
Ключевые слова: гиперпролактинемия, аденома гипофиза, пролактинома.
1. Daly AF, Rixhon M, Adam C et al. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium. J Clin Endocrinol Metab 2006; 91 (12): 4769–75. DOI: 10.1210/jc.2006-1668
2. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin En-docrinol (Oxf) 2010; 72 (3): 377–82. DOI: 10.1111/j.1365-2265.2009.03667.x
3. Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactino-mas: The old and the new. Best Pract Res Clin Endocrinol Metab 2019; 33 (2): 101290. DOI: 10.1016/j.beem.2019.101290
4. Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А. и др. Федеральные кли-нические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии. Проблемы Эн-докринологии 2013; 59 (6): 19–26. [Mel'nichenko G.A., Dzeranova L.K., Pi-garova E.A. et al. Russian Association of endocrinologists national practice guidelines (clinical signs, diagnosis, differential diagnosis, treatment) hyper-prolactinemia. Problems of Endocrinology 2013; 59 (6): 19–26 (in Russian)]. DOI: 10.14341/probl201359619-26
5. Lippi G, Plebani M. Macroprolactin: searching for a needle in a haystack? Clin Chem Lab Med 2016; 54 (4): 519–22. DOI: 10.1515/cclm-2015-1283
6. Barth JH, Lippiatt CM, Gibbons SG, Desborough RA. Observational studies on macroprolactin in a routine clinical laboratory. Clin Chem Lab Med 2018; 56 (8): 1259–62. DOI: 10.1515/cclm-2018-0074
7. Мельниченко Г.А., Гончаров Н.П., Дзеранова Л.К. и др. Клинические и ла-бораторные аспекты исследования изоформ пролактина методами ПЭГ-преципитации и ультрафильтрации. Проблемы эндокринологии 2010; 56 (1): 19–25. [Mel'nichenko G.A., Goncharov N.P., Dzeranova L.K. et al. Clinical and laboratory aspects of investigations into prolactin isoforms by PEG precipitation and ultrafiltration techniques. Problems of Endocrinology 2010; 56 (1): 19–25 (in Russian)]. DOI: 10.14341/probl201056119-25
8. Hekimsoy Z, Kafesçiler S, Güçlü F, Özmen B. The prevalence of hyperprolacti-naemia in overt and subclinical hypothyroidism. Endocr J 2010; 57 (12): 1011–
5. DOI: 10.1507/endocrj.K10E-215
9. Molitch ME. Medication-Induced Hyperprolactinemia. Mayo Clin Proc 2005; 80 (8): 1050–7. DOI: 10.4065/80.8.1050
10. Duskin-Bitan H, Shimon I. Prolactinomas in males: any differences? Pituitary 2020; 23 (1): 52–7. DOI: 10.1007/s11102-019-01009-y
11. Burke WT, Penn DL, Castlen JP et al. Prolactinomas and nonfunctioning adeno-mas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J Neurosurg 2020; 133 (2): 321–8. DOI: 10.3171/2019.3.JNS19121
12. Karavitaki N, Thanabalasingham G, Shore HCA et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroade-noma. Clin Endocrinol (Oxf) 2006; 65 (4): 524–9. DOI: 10.1111/j.1365-2265.2006.02627.x
13. Kawaguchi T, Ogawa Y, Tominaga T. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging. BMC Res Note. 2014; 7 (1):
555. DOI: 10.1186/1756-0500-7-555
14. Huang Y, Ding C, Zhang F et al. Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas. Oncol Lett 2018; 15 (2): 2010–16. DOI: 10.3892/ol.2017.7462
15. Иловайская И.А., Древаль А.В., Кривошеева Ю.Г. и др. Особенности роста макроаденом гипофиза с различной гормональной активностью. Аль-манах клинической медицины 2016; 44 (4): 451–6. [Ilovayskaya I.A., Dreval’ A.V., Krivosheeva Y.G. et al. Growth particulars of pituitary macroadenomas with various hormonal activities. Alm Clin Med 2016; 44 (4): 451–6 (in Rus-sian)]. DOI: 10.18786/2072-0505-2016-44-4-451-456
16. Wright K, Lee M, Escobar N et al. Tumor volume improves preoperative differ-entiation of prolactinomas and nonfunctioning pituitary adenomas. Endocrine 2021; 74 (1): 138–45. DOI: 10.1007/s12020-021-02744-8
17. Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med 2019; 8 (12): 2203. DOI: 10.3390/jcm8122203
18. Rosário PW, Purisch S. Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists. Arq Bras Endocrinol Metabol 2010; 54 (6): 546–9. DOI: 10.1590/S0004-27302010000600006
19. Andersen M, Hagen C, Frystyk J et al. Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 2003; 149 (1): 17–22. DOI: 10.1530/eje.0.1490017
20. Manuylova E, Calvi LM, Hastings C et al. Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Reports 2016; 2016. DOI: 10.1530/EDM-16-0069
21. Labad J, Montalvo I, González-Rodríguez A et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hy-perprolactinaemia: A systematic review and meta-analysis. Schizophr Res 2020; 222: 88–96. DOI: 10.1016/j.schres.2020.04.031
22. Wang AT, Mullan RJ, Lane MA et al. Treatment of hyperprolactinemia: a sys-tematic review and meta-analysis. Syst Rev 2012; 1 (1): 33. DOI: 10.1186/2046-4053-1-33
23. Souteiro P, Belo S, Carvalho D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary 2020; 23 (1): 38–44. DOI: 10.1007/s11102-019-00989-1
24. Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary 2017; 20 (4): 464–70. DOI: 10.1007/s11102-017-0806-x
2. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin En-docrinol (Oxf) 2010; 72 (3): 377–82. DOI: 10.1111/j.1365-2265.2009.03667.x
3. Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactino-mas: The old and the new. Best Pract Res Clin Endocrinol Metab 2019; 33 (2): 101290. DOI: 10.1016/j.beem.2019.101290
4. Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А. и др. Федеральные кли-нические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии. Проблемы Эн-докринологии 2013; 59 (6): 19–26. [Mel'nichenko G.A., Dzeranova L.K., Pi-garova E.A. et al. Russian Association of endocrinologists national practice guidelines (clinical signs, diagnosis, differential diagnosis, treatment) hyper-prolactinemia. Problems of Endocrinology 2013; 59 (6): 19–26 (in Russian)]. DOI: 10.14341/probl201359619-26
5. Lippi G, Plebani M. Macroprolactin: searching for a needle in a haystack? Clin Chem Lab Med 2016; 54 (4): 519–22. DOI: 10.1515/cclm-2015-1283
6. Barth JH, Lippiatt CM, Gibbons SG, Desborough RA. Observational studies on macroprolactin in a routine clinical laboratory. Clin Chem Lab Med 2018; 56 (8): 1259–62. DOI: 10.1515/cclm-2018-0074
7. Мельниченко Г.А., Гончаров Н.П., Дзеранова Л.К. и др. Клинические и ла-бораторные аспекты исследования изоформ пролактина методами ПЭГ-преципитации и ультрафильтрации. Проблемы эндокринологии 2010; 56 (1): 19–25. [Mel'nichenko G.A., Goncharov N.P., Dzeranova L.K. et al. Clinical and laboratory aspects of investigations into prolactin isoforms by PEG precipitation and ultrafiltration techniques. Problems of Endocrinology 2010; 56 (1): 19–25 (in Russian)]. DOI: 10.14341/probl201056119-25
8. Hekimsoy Z, Kafesçiler S, Güçlü F, Özmen B. The prevalence of hyperprolacti-naemia in overt and subclinical hypothyroidism. Endocr J 2010; 57 (12): 1011–
5. DOI: 10.1507/endocrj.K10E-215
9. Molitch ME. Medication-Induced Hyperprolactinemia. Mayo Clin Proc 2005; 80 (8): 1050–7. DOI: 10.4065/80.8.1050
10. Duskin-Bitan H, Shimon I. Prolactinomas in males: any differences? Pituitary 2020; 23 (1): 52–7. DOI: 10.1007/s11102-019-01009-y
11. Burke WT, Penn DL, Castlen JP et al. Prolactinomas and nonfunctioning adeno-mas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J Neurosurg 2020; 133 (2): 321–8. DOI: 10.3171/2019.3.JNS19121
12. Karavitaki N, Thanabalasingham G, Shore HCA et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroade-noma. Clin Endocrinol (Oxf) 2006; 65 (4): 524–9. DOI: 10.1111/j.1365-2265.2006.02627.x
13. Kawaguchi T, Ogawa Y, Tominaga T. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging. BMC Res Note. 2014; 7 (1):
555. DOI: 10.1186/1756-0500-7-555
14. Huang Y, Ding C, Zhang F et al. Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas. Oncol Lett 2018; 15 (2): 2010–16. DOI: 10.3892/ol.2017.7462
15. Иловайская И.А., Древаль А.В., Кривошеева Ю.Г. и др. Особенности роста макроаденом гипофиза с различной гормональной активностью. Аль-манах клинической медицины 2016; 44 (4): 451–6. [Ilovayskaya I.A., Dreval’ A.V., Krivosheeva Y.G. et al. Growth particulars of pituitary macroadenomas with various hormonal activities. Alm Clin Med 2016; 44 (4): 451–6 (in Rus-sian)]. DOI: 10.18786/2072-0505-2016-44-4-451-456
16. Wright K, Lee M, Escobar N et al. Tumor volume improves preoperative differ-entiation of prolactinomas and nonfunctioning pituitary adenomas. Endocrine 2021; 74 (1): 138–45. DOI: 10.1007/s12020-021-02744-8
17. Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med 2019; 8 (12): 2203. DOI: 10.3390/jcm8122203
18. Rosário PW, Purisch S. Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists. Arq Bras Endocrinol Metabol 2010; 54 (6): 546–9. DOI: 10.1590/S0004-27302010000600006
19. Andersen M, Hagen C, Frystyk J et al. Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 2003; 149 (1): 17–22. DOI: 10.1530/eje.0.1490017
20. Manuylova E, Calvi LM, Hastings C et al. Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Reports 2016; 2016. DOI: 10.1530/EDM-16-0069
21. Labad J, Montalvo I, González-Rodríguez A et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hy-perprolactinaemia: A systematic review and meta-analysis. Schizophr Res 2020; 222: 88–96. DOI: 10.1016/j.schres.2020.04.031
22. Wang AT, Mullan RJ, Lane MA et al. Treatment of hyperprolactinemia: a sys-tematic review and meta-analysis. Syst Rev 2012; 1 (1): 33. DOI: 10.1186/2046-4053-1-33
23. Souteiro P, Belo S, Carvalho D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary 2020; 23 (1): 38–44. DOI: 10.1007/s11102-019-00989-1
24. Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary 2017; 20 (4): 464–70. DOI: 10.1007/s11102-017-0806-x